Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of ALN-CIDEB in Adults With Fibrotic MASH
jRCT2031260422Phase 2Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2027
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 2, randomised, double-blind trial of ALN-CIDEB in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percent change from baseline in liver fat by MRI-PDFF. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
ALN-CIDEB
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2031260422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260422.